By: Roger Heyna
The CAP/NSH HQIP Committee has made significant and exciting changes to the HQ-IHC survey beginning in 2020! In the past, this survey has offered four (4) IHC stains per mailing, and the tissues were all biopsy tissues, the same tissues used in the HQ-BX survey.
The new HQ-IHC survey will expand to five (5) IHC stains per mailing. The new focus will be on the primary clinical applications and the recommended positive control tissues for each antibody. Laboratories will receive details about each antibody/tissue offering in the Participant Summary Reports sent to those who participate. This all makes enrollment and participation in this survey much more clinically useful for laboratories.
Look at what we have planned for 2020!
CD20, tonsil resection
Estrogen Receptor, tonsil resection
bcl6, follicular lymphoma
GATA3, bladder biopsy
Pancytokeratin, liver resection
PR, breast core biopsy
PAX5, tonsil resection
NKX3.1, prostatic adenocarcinoma
And there’s more!
In addition to the changes in the HQ-IHC program, there are three (3) new program offerings for 2020: CAP/NSH HistoQIP In-Situ Hybridization (HQ-ISH), Central Nervous System IHC (HQ-NEU), and Melanoma IHC (HQ-MEL). That means the CAP/NSH HistoQIP for 2020 consists of thirteen (13) different quality improvement programs for the clinical, research, and veterinary histology laboratories, whether they be hospital-based or private, independent labs. You can enroll now for these programs to assess your labs quality.
You can view all of the HistoQIP Quality Improvement programs on pages 271-277 in the new 2020 Surveys and Anatomic Pathology Education Programs catalog. Follow this link to view the new 2020 CAP Surveys catalog: https://documents.cap.org/documents/2020-survey-catalog.pdf